<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184663</url>
  </required_header>
  <id_info>
    <org_study_id>APACaP D13-1</org_study_id>
    <secondary_id>2014-A00228-39</secondary_id>
    <nct_id>NCT02184663</nct_id>
  </id_info>
  <brief_title>Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer</brief_title>
  <official_title>Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adapted Physical Activity (APA) program may provide an opportunity to improve symptoms for
      patients with unresectable pancreatic cancer.

      Thereby, it is proposed to conduct an open trial to assess effects of the APA program in such
      population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The benefit of Adapted Physical Activity (APA) has been demonstrated after cancer diagnosis
      in term of symptomatic improvement: reducing fatigue, pain and improving the quality of life,
      psychological and emotional state, and adherence to treatment.

      The aim of the study is to assess the effects of an APA program in pancreatic cancer
      population treated by usual chemotherapy.

      200 randomized patients are required.

      The program is organized in 16 weeks. During the trial, assessments include: aerobic
      exercises, muscular strength, six-minute walk test, body composition (bioimpedance, L3
      CT-scan), level of physical activity - International Physical Activity Questionnaire - (IPAQ
      questionnaire), fatigue - Multidimensional Fatigue Inventory - (MFI-20 questionnaire),
      quality of life - EORTC Quality of Life questionnaire C-30 - (EORTC QLQ-30 questionnaire),
      depression symptom - Hospital Anxiety and depression scale - (HADS questionnaire), pain
      (Brief Pain Inventory Short form), and nutritional evaluation (BMI, ingests EVA).

      Furthermore, relationships between insulin resistance, insulin secretion, Insulin like Growth
      Factor 1 (IGF-1) and pancreatic carcinogenesis exist. APA may improve the quality of life in
      decreasing insulin-resistance, insulin secretion and IGF-1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multidimensional Fatigue Inventory - (MFI-20 questionnaire)</measure>
    <time_frame>At 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life - EORTC Quality of Life Questionnaire C-30 - (EORTC QLQ-30 questionnaire)</measure>
    <time_frame>At 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To deterioration (TTD)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory Short form questionnaire</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient depression scale - HADS questionnaire</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Nutritional Status will be measured by weigth, Body Mass Index, body composition, EVA ingests, caloric intake and protidic, albumin/prealbumin, inflammation markers (PNN and CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity evaluation - IPAQ questionnaire</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Six minutes walk test, dyspnea scale, Borg scale, muscular pain, strength test with bands and compliance program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse events (AE) grade 3 -4</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accompanying partner depression scale (HADS questionnaire)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General state - Performance status OMS</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue scale (EVA fatigue)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MFI-20 and EORTC QLQ C-30 evaluation</measure>
    <time_frame>at 6, 12 et 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medico-economic evaluation</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analog scale for pain</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analgesic consumption</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiolytic / antidepressant consumption</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Unresectable Locally Advanced Cancer</condition>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Standard care without APA program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care with APA program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>without APA program</intervention_name>
    <description>Control Arm : chemotherapy alone</description>
    <arm_group_label>Standard care without APA program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>APA program</intervention_name>
    <description>Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)</description>
    <arm_group_label>standard care with APA program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven non resectable pancreatic adenocarcinoma

          -  Indication of palliative chemotherapy

          -  Life expectancy ≥ 3 months

          -  Eastern Cooperative oncology group (ECOG) - Performance status ≤2

          -  Age ≥18 years old

          -  At least one measurable lesion as assessed by CT-scan or MRI (Magnetic resonance
             Imaging)

          -  Identified Accompanying partner Adapted Physical Activity (AAPA)

          -  Signed and dated informed consent

          -  Registration in a National Health Care System (CMU included for France)

        Exclusion Criteria:

          -  Previous Cerebrovascular accident or myocardial infarction &lt;6months

          -  Uncontrolled hypertension.

          -  Severe cardiovascular or respiratory disease

          -  Severe cognitive or psychiatric disorder

          -  Severe motor and/or sensory neuropathy

          -  Rheumatologic or orthopedic problem or bone lesions with a fracture risk

          -  Others comorbidities contra-indicated physical exercises

          -  Patient protected by the law - Guardianship and trusteeship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Hammel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal HAMMEL, PhD</last_name>
    <phone>+33140875651</phone>
    <email>pascal.hammel@bjn.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric LECAILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cédric LECAILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Philippe METGES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Philippe METGES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal HAMMEL, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Pascal HAMMEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe TOURNIGAND, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe TOURNIGAND, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger FAROUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roger FAROUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Françoise DESSEIGNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Françoise DESSEIGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis PERE VERGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Denis PERE VERGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves RINALDI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves RINALDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Mont de Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérome DAUBA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérome DAUBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Belfort</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano KIM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefano KIM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GOLDWASSER, MD</last_name>
    </contact>
    <investigator>
      <last_name>François GOLDWASSER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Line GARCIA LARNICOL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Line GARCIA LARNICOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien VOLET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien VOLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>May MABRO, MD</last_name>
    </contact>
    <investigator>
      <last_name>May MABRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry CONROY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry CONROY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>GERCOR</keyword>
  <keyword>Adapted physical activity (APA)</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

